Publications
Ruan DY, Wu HX, Xu Y, Munster PN, Deng Y, Richardson G, Yan D, Lee MA, Lee KW, Pan H, Hager S, Li X, Wei S, Hou X, Underhill C, Millward M, Nordman I, Zhang J, Shan J, Han G, Grewal J, Gadgeel SM, Sanborn RE, Huh SJ, Hu X, Zhang Y, Xiang Z, Luo L, Xie X, Shi Z, Wang Y, Zhang L, Wang F, Xu RH. Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Signal transduction and targeted therapy. 2025. PMID: 40523897
Yang H, Song H, Yip E, Gilpatrick T, Chang K, Allegakoen P, Lu KL, Hui K, Pham JH, Kasap C, Kumar V, Gayle J, Stohr BA, Cornelia Ding CK, Wiita AP, Meng MV, Chou J, Porten SP, Huang FW. Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature communications. 2025. PMID: 40527915
Yang H, Song H, Yip E, Gilpatrick T, Chang K, Allegakoen P, Lu KL, Hui K, Pham JH, Kasap C, Kumar V, Gayle J, Stohr BA, Cornelia Ding CK, Wiita AP, Meng MV, Chou J, Porten SP, Huang FW. Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature communications. 2025. PMID: 40527915
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A. Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. ESMO open. 2025. PMID: 40532364
Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO precision oncology. 2025. PMID: 40526879
Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO precision oncology. 2025. PMID: 40526879
H. Geng, M. Randall, A. Ballapuram, L. Chen, C. Yung, M. Lu, C. Lowell, J. L. Rubenstein. THE TOLL-LIKE RECEPTOR 7/8 PATHWAY HAS PROGNOSTIC SIGNIFICANCE AND IS A THERAPEUTIC TARGET IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:
D. A. Solomon, H. Geng, M. Randall, R. Sobel, J. Cleveland, A. Ballapuram, L. Chen, M. Lu, S. Cha, C. Lowell, W. P. Devine, J. L. Rubenstein. THERAPY-DRIVEN EVOLUTION AND INTRATUMORAL GENETIC HETEROGENEITY IN CNS LYMPHOMAS. Hematological Oncology. 2025. PMID:
Najjar YG, Orloff M, Mitchell TC, Bowles TL, Betof Warner A, Bollin K, Chandra S, Cohen JV, Eroglu Z, Funchain P, Gaughan E, Glitza Oliva I, Hsu S, Hu-Lieskovan S, Kennedy LB, Truong TG, McKean M, Mehnert J, Moon H, Tsai KK, Wilson M, Tran T, Buchbinder EI, Fecher LA, Guild S, Patel SP. Proceedings of the seventh annual Women in Melanoma Conference. Therapeutic advances in medical oncology. 2025. PMID: 40535733
Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Pikman Y, Cheng ML, Logan AC, Stieglitz E, Smith CC. Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia. bioRxiv : the preprint server for biology. 2025. PMID: 40661530
Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Pikman Y, Cheng ML, Logan AC, Stieglitz E, Smith CC. Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia. bioRxiv : the preprint server for biology. 2025. PMID: 40661530
Nikita Baclig, Andrew Soliman, Saya Jacob, Alexis LeVee, Samantha Fisch, Carolyn Face, Madhuri Chengappa, Saliha Chaudhry, Dame Idossa, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Anne Blaes, Hope S. Rugo, Melissa Lechner, Kelly E. McCann. Abstract P1-04-07: Incidence and Risk Factors of Immune-Related Adverse Events in Metastatic Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:
Madhuri Chengappa, Thejaswi K Poonacha, Nikitha Vobugari, Go Nishikawa, Saya Jacob, Samantha Fisch, Carolyn Face, Alexis LeVee, Nikita V. Baclig, Andrew Soliman, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Joanne Mortimer, Kelly McCann, Hope S. Rugo, Dame Idossa, Anne Blaes. Abstract P1-12-04: Correlation between Immune-Related Adverse Events (irAE) and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Immune Checkpoint Inhibitors (ICI): a multi-institutional study. Clinical Cancer Research. 2025. PMID:
Fukuda K, Nanjo S, Takeuchi S, Chakrabarti T, Brown T, Dev Sahadevan SW, Arai S, Sato S, Kotani H, Nishiyama A, Sakaguchi H, Ohtsubo K, Taniguchi H, Blakely CM, Bivona TG, Yano S. Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025. PMID: 40518016
Laura A. Huppert, Kelsey Kuwahara, Maggie Zhou, Mia Salans, Samantha Fisch, Jo Chien, Melanie Majure, Hope Rugo, Lauren Boreta, Steve E. Braunstein, Ramin A. Morshed, Harish N. Vasudevan, Michelle E. Melisko. Abstract P5-10-01: Demographic, Clinical Characteristics, and Overall Survival of Patients with Metastatic Breast Cancer and Brain Metastases: A Single Center Retrospective Cohort Study. Clinical Cancer Research. 2025. PMID:
Fukuda K, Nanjo S, Takeuchi S, Chakrabarti T, Brown T, Dev Sahadevan SW, Arai S, Sato S, Kotani H, Nishiyama A, Sakaguchi H, Ohtsubo K, Taniguchi H, Blakely CM, Bivona TG, Yano S. Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2025. PMID: 40518016
Samantha Fisch, Joshua Chin, Laura Quintal, Melanie Majure, Michelle Melisko, Jo Chien, Hope S. Rugo, Laura A. Huppert. Abstract P5-12-25: Single-center retrospective cohort study evaluating neutropenia and growth factor use with sacituzumab govitecan in patients with HR+/HER2- and triple negative metastatic breast cancer. Clinical Cancer Research. 2025. PMID:
Alexis LeVee, Saya Jacob, Samantha Fisch, Carolyne Face, Madhuri Chengappa, Saliha Chaudhry, Nikita Baclig, Andrew Soliman, Nora Ruel, Megan Wong, Karen Tsai, Irene Kang, Laura Huppert, Laura Quintal, Michelle Melisko, Melanie Majure, Jo Chien, Melissa Lechner, Dame Idossa, Anne Blaes, Kelly McCann, Hope S. Rugo, Joanne Mortimer. Abstract PS5-03: Incidence and Risk Factors of Immune-Related Adverse Events in Early-Stage Breast Cancer Patients: Findings from a Multi-Institutional Study. Clinical Cancer Research. 2025. PMID:
Tarantino P, Rugo HS, Curigliano G, O'Shaughnessy JA, Janni W, Jhaveri K, Mouabbi J, Brufsky A, Hamilton E, O'Regan R, Santarsiero L, Akdere M, Ye F, Scotchmer A, Graff SL. Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysis. ESMO open. 2025. PMID: 40516131
Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2025. PMID: 40504161